Emerald Advisers’s NovoCure NVCR Stock Holding History

Emerald Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,311	Closed	-$16.9K	–	259
2025 Q3	$16.9K	Sell	1,311 -460,054	-100%	-$6.15M	﹤0.01%	253
2025 Q2	$8.21M	Sell	461,365 -76,884	-14%	-$1.34M	0.3%	102
2025 Q1	$9.59M	Sell	538,249 -9,308	-2%	-$211K	0.43%	82
2024 Q4	$16.3M	Buy	+547,557	New	+$11.6M	0.63%	67
2021 Q3	–	Sell	-2,033	Closed	-$451K	–	269
2021 Q2	$451K	Buy	+2,033	New	+$395K	0.02%	197

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Emerald Advisers's NVCR Position: Q4 2025 in Review

Emerald Advisers sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 1,311 shares — an estimated $16.9K sold.

Emerald Advisers first reported a position in NVCR in Q2 2021 and held it in 5 quarters. The position peaked at $16.3M in Q4 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Emerald Advisers reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Emerald Advisers sold 1,311 NovoCure shares in Q4 2025, an estimated $16.9K.
Emerald Advisers first reported a position in NovoCure in Q2 2021 and held it in 5 quarters.
Emerald Advisers's NovoCure position peaked at $16.3M in Q4 2024.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Emerald Advisers's 13F filing for Q4 2025, filed 9 Feb 2026.